ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: SA-PO0880

Overlapping IgM Mesangioproliferative Glomerulonephritis (GN) and ANCA-Associated Crescentic GN Associated with Hydralazine

Session Information

Category: Glomerular Diseases

  • 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics

Authors

  • Reyes, Luis M, The University of Texas at Tyler School of Medicine, Tyler, Texas, United States
  • Weyer, Alyssa Caparas, The University of Texas at Tyler School of Medicine, Tyler, Texas, United States
  • Greenwell, Mark W., The University of Texas at Tyler School of Medicine, Tyler, Texas, United States
Introduction

Hydralazine, a commonly used antihypertensive agent, has been associated with the development of anti-neutrophilic cytoplasmic antibody-glomerulonephritis (ANCA-GN) in susceptible individuals. Hydralazine-induced ANCA-GN can mimic primary ANCA-GN with necrotizing and crescentic glomerulonephritis. However, distinct pathological differences have been observed. Compared to primary ANCA-GN, hydralazine-associated cases exhibit a higher frequency of mesangial hypercellularity (30% vs 5%) and a lower incidence of pauci-immune features (77 vs 100%).1

Case Description

Patient is an 85-year-old woman with a history of asthma, hypertension, hyperlipidemia, and pulmonary hypertension who was evaluated for elevated creatinine in the 3 to 4 range and reduced glomerular filtration rate of 11 mL/min/1.73m2. She reported generalized fatigue, unintentional ninety-pound weight loss, and intermittent nausea and diarrhea. She had no prior history of acute kidney injury, kidney stones, NSAID use, contrast exposure, or new medications. Initial work up consisted of serum creatinine 4.42 mg/dL, eGFR 9 mL/min/1.73m2, hemoglobin 7 g/dL, sub nephrotic range proteinuria, large blood with 80-100 rbc/hpf, antinuclear antibody titer 1:1280, p-ANCA titer 1:640, and myeloperoxidase antibody greater than 8 units. Renal ultrasound showed 2 simple cysts on the right kidney but was otherwise unremarkable. Kidney biopsy showed IgM dominant mesangioproliferative glomerulonephritis with rare crescents. She was diagnosed with hydralazine induced ANCA vasculitis overlapping with IgM immune complex glomerulonephritis with crescent formation. Hydralazine was discontinued, and she was started on rituximab infusions and high dose steroids. She responded well to treatment with her creatinine and eGFR improving to 2.6 mg/dl and 19 ml/min/1.73m2.

Discussion

This case is notable for the presence of perinuclear anti-neutrophil cytoplasmic antibodies (p-ANCA), myeloperoxidase (MPO) antibodies, and IgM mesangioproliferative glomerulonephritis with rare crescent formation. Given the widespread use of hydralazine, hydralazine-induced glomerulonephritis (GN) should remain a consideration in the differential diagnosis. Management typically involves immunosuppressive therapy and discontinuation of hydralazine, with clinical outcomes comparable to those observed in primary ANCA-associated GN.

Digital Object Identifier (DOI)